H2N2V1, PubMed, Checkpoint, bibRecord, 000019

Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.

Identifieur interne : 000019 ( PubMed/Checkpoint ); précédent : 000018; suivant : 000020

Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.

Auteurs : Svetlana Shcherbik [États-Unis] ; Paul Carney [États-Unis] ; Nicholas Pearce [États-Unis] ; James Stevens [États-Unis] ; Vivien G. Dugan [États-Unis] ; David E. Wentworth [États-Unis] ; Tatiana Bousse [États-Unis]

Source :

Virology [ 1096-0341 ] ; 2018.

RBID : pubmed:30014859

Descripteurs français

English descriptors

KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (isolation & purification), Antibodies, Viral (immunology), Antibodies, Viral (isolation & purification), Cell Line, Cold Temperature, Humans, Influenza A Virus, H2N2 Subtype (growth & development), Influenza A Virus, H2N2 Subtype (immunology), Influenza A Virus, H2N2 Subtype (isolation & purification), Influenza Vaccines (immunology), Influenza Vaccines (isolation & purification), Neuraminidase (immunology), Reassortant Viruses (growth & development), Reassortant Viruses (immunology), Reassortant Viruses (isolation & purification), Technology, Pharmaceutical (methods), Vaccines, Attenuated (immunology), Vaccines, Attenuated (isolation & purification), Viral Proteins (immunology), Virus Cultivation (methods).
MESH :
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Viral, Influenza Vaccines, Neuraminidase, Vaccines, Attenuated, Viral Proteins.
- chemical , isolation & purification : Antibodies, Monoclonal, Antibodies, Viral, Influenza Vaccines, Vaccines, Attenuated.
- growth & development : Influenza A Virus, H2N2 Subtype, Reassortant Viruses.
- immunology : Influenza A Virus, H2N2 Subtype, Reassortant Viruses.
- isolation & purification : Influenza A Virus, H2N2 Subtype, Reassortant Viruses.
- methods : Technology, Pharmaceutical, Virus Cultivation.
- Animals, Cell Line, Cold Temperature, Humans.

Abstract

Cold adapted influenza virus A/Leningrad/134/17/57 (H2N2) is a reliable master donor virus (Len/17-MDV) for preparing live attenuated influenza vaccines (LAIV). LAIVs are 6:2 reasortants that contain 6 segments of Len/17-MDV and the hemagglutinin (HA) and neuraminidase (NA) of contemporary circulating influenza A viruses. The problem with the classical reassortment procedure used to generate LAIVs is that there is limited selection pressure against NA of the Len/17-MDV resulting in 7:1 reassortants with desired HA only, which are not suitable LAIVs. The monoclonal antibodies (mAb) directed against the N2 of Len/17-MDV were generated. 10C4-8E7 mAb inhibits cell-to-cell spread of viruses containing the Len/17-MDV N2, but not viruses with the related N2 from contemporary H3N2 viruses. 10C4-8E7 antibody specifically inhibited the Len/17-MDV replication in vitro and in ovo but didn't inhibit replication of H3N2 or H1N1pdm09 reassortants. Our data demonstrate that addition of 10C4-8E7 in the classical reassortment improves efficiency of LAIV production.

DOI: 10.1016/j.virol.2018.07.005
PubMed: 30014859

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000019
to stream PubMed, to step Curation: 000019

Links to Exploration step

pubmed:30014859

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.</title>
<author><name sortKey="Shcherbik, Svetlana" sort="Shcherbik, Svetlana" uniqKey="Shcherbik S" first="Svetlana" last="Shcherbik">Svetlana Shcherbik</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carney, Paul" sort="Carney, Paul" uniqKey="Carney P" first="Paul" last="Carney">Paul Carney</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pearce, Nicholas" sort="Pearce, Nicholas" uniqKey="Pearce N" first="Nicholas" last="Pearce">Nicholas Pearce</name>
<affiliation wicri:level="1"><nlm:affiliation>Battelle, Atlanta, GA 30329, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Battelle, Atlanta, GA 30329</wicri:regionArea>
<wicri:noRegion>GA 30329</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stevens, James" sort="Stevens, James" uniqKey="Stevens J" first="James" last="Stevens">James Stevens</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dugan, Vivien G" sort="Dugan, Vivien G" uniqKey="Dugan V" first="Vivien G" last="Dugan">Vivien G. Dugan</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wentworth, David E" sort="Wentworth, David E" uniqKey="Wentworth D" first="David E" last="Wentworth">David E. Wentworth</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bousse, Tatiana" sort="Bousse, Tatiana" uniqKey="Bousse T" first="Tatiana" last="Bousse">Tatiana Bousse</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States. Electronic address: gsx8@cdc.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30014859</idno>
<idno type="pmid">30014859</idno>
<idno type="doi">10.1016/j.virol.2018.07.005</idno>
<idno type="wicri:Area/PubMed/Corpus">000019</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000019</idno>
<idno type="wicri:Area/PubMed/Curation">000019</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000019</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000019</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000019</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.</title>
<author><name sortKey="Shcherbik, Svetlana" sort="Shcherbik, Svetlana" uniqKey="Shcherbik S" first="Svetlana" last="Shcherbik">Svetlana Shcherbik</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Carney, Paul" sort="Carney, Paul" uniqKey="Carney P" first="Paul" last="Carney">Paul Carney</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pearce, Nicholas" sort="Pearce, Nicholas" uniqKey="Pearce N" first="Nicholas" last="Pearce">Nicholas Pearce</name>
<affiliation wicri:level="1"><nlm:affiliation>Battelle, Atlanta, GA 30329, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Battelle, Atlanta, GA 30329</wicri:regionArea>
<wicri:noRegion>GA 30329</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stevens, James" sort="Stevens, James" uniqKey="Stevens J" first="James" last="Stevens">James Stevens</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dugan, Vivien G" sort="Dugan, Vivien G" uniqKey="Dugan V" first="Vivien G" last="Dugan">Vivien G. Dugan</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wentworth, David E" sort="Wentworth, David E" uniqKey="Wentworth D" first="David E" last="Wentworth">David E. Wentworth</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bousse, Tatiana" sort="Bousse, Tatiana" uniqKey="Bousse T" first="Tatiana" last="Bousse">Tatiana Bousse</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States. Electronic address: gsx8@cdc.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea>
<wicri:noRegion>GA 30333</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Virology</title>
<idno type="eISSN">1096-0341</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibodies, Monoclonal (isolation & purification)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibodies, Viral (isolation & purification)</term>
<term>Cell Line</term>
<term>Cold Temperature</term>
<term>Humans</term>
<term>Influenza A Virus, H2N2 Subtype (growth & development)</term>
<term>Influenza A Virus, H2N2 Subtype (immunology)</term>
<term>Influenza A Virus, H2N2 Subtype (isolation & purification)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (isolation & purification)</term>
<term>Neuraminidase (immunology)</term>
<term>Reassortant Viruses (growth & development)</term>
<term>Reassortant Viruses (immunology)</term>
<term>Reassortant Viruses (isolation & purification)</term>
<term>Technology, Pharmaceutical (methods)</term>
<term>Vaccines, Attenuated (immunology)</term>
<term>Vaccines, Attenuated (isolation & purification)</term>
<term>Viral Proteins (immunology)</term>
<term>Virus Cultivation (methods)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (isolement et purification)</term>
<term>Anticorps monoclonaux (immunologie)</term>
<term>Anticorps monoclonaux (isolement et purification)</term>
<term>Basse température</term>
<term>Culture virale ()</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Protéines virales (immunologie)</term>
<term>Sialidase (immunologie)</term>
<term>Sous-type H2N2 du virus de la grippe A (croissance et développement)</term>
<term>Sous-type H2N2 du virus de la grippe A (immunologie)</term>
<term>Sous-type H2N2 du virus de la grippe A (isolement et purification)</term>
<term>Technologie pharmaceutique ()</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (isolement et purification)</term>
<term>Vaccins atténués (immunologie)</term>
<term>Vaccins atténués (isolement et purification)</term>
<term>Virus recombinants (croissance et développement)</term>
<term>Virus recombinants (immunologie)</term>
<term>Virus recombinants (isolement et purification)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Viral</term>
<term>Influenza Vaccines</term>
<term>Neuraminidase</term>
<term>Vaccines, Attenuated</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Viral</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Reassortant Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps monoclonaux</term>
<term>Protéines virales</term>
<term>Sialidase</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Reassortant Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Reassortant Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps monoclonaux</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Technology, Pharmaceutical</term>
<term>Virus Cultivation</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Cold Temperature</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Basse température</term>
<term>Culture virale</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Technologie pharmaceutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cold adapted influenza virus A/Leningrad/134/17/57 (H2N2) is a reliable master donor virus (Len/17-MDV) for preparing live attenuated influenza vaccines (LAIV). LAIVs are 6:2 reasortants that contain 6 segments of Len/17-MDV and the hemagglutinin (HA) and neuraminidase (NA) of contemporary circulating influenza A viruses. The problem with the classical reassortment procedure used to generate LAIVs is that there is limited selection pressure against NA of the Len/17-MDV resulting in 7:1 reassortants with desired HA only, which are not suitable LAIVs. The monoclonal antibodies (mAb) directed against the N2 of Len/17-MDV were generated. 10C4-8E7 mAb inhibits cell-to-cell spread of viruses containing the Len/17-MDV N2, but not viruses with the related N2 from contemporary H3N2 viruses. 10C4-8E7 antibody specifically inhibited the Len/17-MDV replication in vitro and in ovo but didn't inhibit replication of H3N2 or H1N1pdm09 reassortants. Our data demonstrate that addition of 10C4-8E7 in the classical reassortment improves efficiency of LAIV production.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30014859</PMID>
<DateCompleted><Year>2018</Year>
<Month>08</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>02</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0341</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>522</Volume>
<PubDate><Year>2018</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>Virology</Title>
<ISOAbbreviation>Virology</ISOAbbreviation>
</Journal>
<ArticleTitle>Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.</ArticleTitle>
<Pagination><MedlinePgn>65-72</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0042-6822(18)30206-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2018.07.005</ELocationID>
<Abstract><AbstractText>Cold adapted influenza virus A/Leningrad/134/17/57 (H2N2) is a reliable master donor virus (Len/17-MDV) for preparing live attenuated influenza vaccines (LAIV). LAIVs are 6:2 reasortants that contain 6 segments of Len/17-MDV and the hemagglutinin (HA) and neuraminidase (NA) of contemporary circulating influenza A viruses. The problem with the classical reassortment procedure used to generate LAIVs is that there is limited selection pressure against NA of the Len/17-MDV resulting in 7:1 reassortants with desired HA only, which are not suitable LAIVs. The monoclonal antibodies (mAb) directed against the N2 of Len/17-MDV were generated. 10C4-8E7 mAb inhibits cell-to-cell spread of viruses containing the Len/17-MDV N2, but not viruses with the related N2 from contemporary H3N2 viruses. 10C4-8E7 antibody specifically inhibited the Len/17-MDV replication in vitro and in ovo but didn't inhibit replication of H3N2 or H1N1pdm09 reassortants. Our data demonstrate that addition of 10C4-8E7 in the classical reassortment improves efficiency of LAIV production.</AbstractText>
<CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shcherbik</LastName>
<ForeName>Svetlana</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Carney</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pearce</LastName>
<ForeName>Nicholas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Battelle, Atlanta, GA 30329, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stevens</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dugan</LastName>
<ForeName>Vivien G</ForeName>
<Initials>VG</Initials>
<AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wentworth</LastName>
<ForeName>David E</ForeName>
<Initials>DE</Initials>
<AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bousse</LastName>
<ForeName>Tatiana</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States. Electronic address: gsx8@cdc.gov.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID>
<Agency>Intramural CDC HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>07</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Virology</MedlineTA>
<NlmUniqueID>0110674</NlmUniqueID>
<ISSNLinking>0042-6822</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="C487630">NA protein, influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003080" MajorTopicYN="N">Cold Temperature</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName>
<QualifierName UI="Q000254" MajorTopicYN="Y">growth & development</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName>
<QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013678" MajorTopicYN="N">Technology, Pharmaceutical</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014776" MajorTopicYN="N">Virus Cultivation</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Classical reassortment</Keyword>
<Keyword MajorTopicYN="Y">Influenza</Keyword>
<Keyword MajorTopicYN="Y">Live vaccine</Keyword>
<Keyword MajorTopicYN="Y">Monoclonal antibody</Keyword>
<Keyword MajorTopicYN="Y">Neuraminidase</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>04</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>07</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>07</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>7</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>8</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>7</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30014859</ArticleId>
<ArticleId IdType="pii">S0042-6822(18)30206-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.virol.2018.07.005</ArticleId>
<ArticleId IdType="pmc">PMC6498426</ArticleId>
<ArticleId IdType="mid">NIHMS1024869</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Rev Med Virol. 1999 Oct-Dec;9(4):237-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10578119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2000 Mar;181(3):1133-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10720541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2001;260:171-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11443873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 May 15;20(16):2082-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11972977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2002;15(2):295-323</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12081014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 2004 Jan;59(1):1-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14723616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17027-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15569942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Dec;80(23):11756-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16971435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Nov;82(21):10493-501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18715929</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2008 Nov;2(6):193-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2010 Nov;9(11):1325-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21087110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2011 Jul;5(4):288-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21651740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Jul 1;29 Suppl 1:A29-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21684425</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Jul 1;29 Suppl 1:A40-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21684428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2011 Sep 15;204(6):845-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21846636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2011 Aug;10(8):1131-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21854309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Mol Biol. 2012;865:147-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22528158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2012 Aug;11(8):939-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23002975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Sep;7(5):645-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23575174</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2014 Jan;101:93-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24239666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Mar 19;9(3):e92580</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24647786</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Microbiol J. 2014 Jul 11;8:59-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25132869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Feb;89(3):1550-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25392225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Feb 10;6:6114</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25668439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Host Microbe. 2015 Mar 11;17(3):295-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25766291</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2015 Jul;14(7):963-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25864428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Sep 22;33(39):5110-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26296497</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2015 Sep 25;10(9):e0138951</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26405798</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2016 Jan;227:33-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26519883</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Oct 26;34(45):5436-5441</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27593158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Vis Exp. 2016 Sep 06;(115):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27684188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2016 Nov;135:48-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27713074</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Epidemiol Rep. 2018;5(1):1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29503792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 1977 Jul-Aug;(4):387-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">335659</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 1983 Jul;27(4):311-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6195900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 1996;74(1):77-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8653819</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Shcherbik, Svetlana" sort="Shcherbik, Svetlana" uniqKey="Shcherbik S" first="Svetlana" last="Shcherbik">Svetlana Shcherbik</name>
</noRegion>
<name sortKey="Bousse, Tatiana" sort="Bousse, Tatiana" uniqKey="Bousse T" first="Tatiana" last="Bousse">Tatiana Bousse</name>
<name sortKey="Carney, Paul" sort="Carney, Paul" uniqKey="Carney P" first="Paul" last="Carney">Paul Carney</name>
<name sortKey="Dugan, Vivien G" sort="Dugan, Vivien G" uniqKey="Dugan V" first="Vivien G" last="Dugan">Vivien G. Dugan</name>
<name sortKey="Pearce, Nicholas" sort="Pearce, Nicholas" uniqKey="Pearce N" first="Nicholas" last="Pearce">Nicholas Pearce</name>
<name sortKey="Stevens, James" sort="Stevens, James" uniqKey="Stevens J" first="James" last="Stevens">James Stevens</name>
<name sortKey="Wentworth, David E" sort="Wentworth, David E" uniqKey="Wentworth D" first="David E" last="Wentworth">David E. Wentworth</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000019 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000019 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:30014859
   |texte=   Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:30014859" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.

Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki